Publications (original articles or review articles) published in 2022 from OUS - Section for Cellular Therapy
10 publications found
CAR-Ts: new perspectives in cancer therapy
FEBS Lett, 596 (4), 403-416
DOI 10.1002/1873-3468.14270, PubMed 34978080
PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells
J Immunother Cancer, 10 (1)
DOI 10.1136/jitc-2021-002500, PubMed 35078921
Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination
J Transl Med, 20 (1), 419
DOI 10.1186/s12967-022-03624-z, PubMed 36089578
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials
J Immunother Cancer, 10 (5)
DOI 10.1136/jitc-2021-004345, PubMed 35613827
How CAR T Cells Breathe
Cells, 11 (9)
DOI 10.3390/cells11091454, PubMed 35563759
Mechanism of CD79A and CD79B Support for IgM+ B Cell Fitness through B Cell Receptor Surface Expression
J Immunol, 209 (10), 2042-2053
DOI 10.4049/jimmunol.2200144, PubMed 36426942
T cell receptor repertoire sequencing reveals chemotherapy-driven clonal expansion in colorectal liver metastases
Gigascience, 12
DOI 10.1093/gigascience/giad032, PubMed 37161965
A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT)
Front Oncol, 12, 1031232
DOI 10.3389/fonc.2022.1031232, PubMed 36439452
Emerging Biomarkers for Immunotherapy in Glioblastoma
Cancers (Basel), 14 (8)
DOI 10.3390/cancers14081940, PubMed 35454848
ATMP development and pre-GMP environment in academia: a safety net for early cell and gene therapy development and manufacturing
Immunooncol Technol, 16, 100099
DOI 10.1016/j.iotech.2022.100099, PubMed 36389443